S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Phio Pharmaceuticals (PHIO) Stock Forecast, Price & News

+0.02 (+2.24%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
267,500 shs
Average Volume
2.72 million shs
Market Capitalization
$9.66 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Phio Pharmaceuticals logo

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$1.62 per share


Net Income
$-13.29 million
Pretax Margin




Free Float
Market Cap
$9.66 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.03 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

Is Phio Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals
or view top-rated stocks.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 238,100 shares, a drop of 78.7% from the April 15th total of 1,120,000 shares. Based on an average daily volume of 3,340,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.8% of the shares of the stock are short sold.
View Phio Pharmaceuticals' Short Interest

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Phio Pharmaceuticals

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) released its earnings results on Friday, May, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.11.
View Phio Pharmaceuticals' earnings history

What price target have analysts set for PHIO?

1 brokerages have issued 1-year price objectives for Phio Pharmaceuticals' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Phio Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 748.1% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Phio Pharmaceuticals' key executives?
Phio Pharmaceuticals' management team includes the following people:
  • Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D., Pres, CEO & Director (Age 47, Pay $583.14k)
  • Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 36)
What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.23%), Cetera Investment Advisers (0.66%), Renaissance Technologies LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends for Phio Pharmaceuticals

Which institutional investors are buying Phio Pharmaceuticals stock?

PHIO stock was acquired by a variety of institutional investors in the last quarter, including Cetera Investment Advisers, Renaissance Technologies LLC, and Vanguard Group Inc.. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara.
View insider buying and selling activity for Phio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $0.71.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals has a market capitalization of $9.66 million and generates $20 thousand in revenue each year. The company earns $-13.29 million in net income (profit) each year or ($0.920010) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 12 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at (508) 767-3861, via email at [email protected], or via fax at 508-767-3862.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.